Imfinzi: Clinical Trials

19 trials of Imfinzi, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 recruiting, 5 active not recruiting, 5 completed, 1 not yet recruiting. 19 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 319Recruiting 8, Active not recruiting 5, Completed 5, Not yet recruiting 1
Phase 24Completed 2, Not yet recruiting 1, Recruiting 1

Follow Imfinzi: new trials by email Literature Review of Imfinzi trials Research Report on Imfinzi

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma
Phase 2 / Phase 3Not yet recruitingECOG-ACRIN Cancer Research Group3362027-01-112026-08-14
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
Phase 3RecruitingNRG Oncology2262026-02-262026-08-17
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Rilvegostomig, Durvalumab, Gemcitabine/Cisplatin - Biliary Tract Cancer
Phase 3RecruitingAstraZeneca11002025-12-042026-09-28
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
Biospecimen Collection, Ceralasertib, Computed Tomography - Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Phase 3Active not recruitingNational Cancer Institute (NCI)6302025-08-072026-09-21
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Biospecimen Collection, Computed Tomography, Durvalumab - Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Phase 3RecruitingNational Cancer Institute (NCI)3062025-04-012026-11-19
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Biospecimen Collection, Cyclophosphamide, Doxorubicin - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Phase 3RecruitingNational Cancer Institute (NCI)36802023-11-272026-11-12
A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)
durvalumab - Biliary Tract Cancers
Phase 3CompletedAstraZeneca1162023-07-212025-04-22
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Carboplatin, Cisplatin, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8
Phase 3RecruitingNRG Oncology4742023-07-122026-08-17
Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)
Durvalumab, low-dose PCI - Carcinoma, Non-Small-Cell Lung
Phase 3Active not recruitingAssociation NVALT Studies1702021-12-062025-01-29
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Biopsy Procedure, Biospecimen Collection, Cisplatin - Renal Pelvis and Ureter Urothelial Carcinoma
Phase 2 / Phase 3RecruitingNational Cancer Institute (NCI)1312021-11-122026-11-18
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
Pelvic external beam radiotherapy, Chemotherapy, Durvalumab - Endometrial Cancer
Phase 3RecruitingLeiden University Medical Center3162021-11-112026-10-08
Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC
Durvalumab, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer, NSCLC, Stage III
Phase 3RecruitingStanford University482021-08-252026-09-30
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
Durvalumab, Tremelimumab, Enfortumab Vedotin - Muscle Invasive Bladder Cancer
Phase 3Active not recruitingAstraZeneca7122021-08-052026-06-04
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab - Mesothelioma, Pleural Mesothelioma
Phase 3CompletedPrECOG, LLC.2142021-02-182026-10-22
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
Carboplatin, Cisplatin, Durvalumab - Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Phase 3Active not recruitingNational Cancer Institute (NCI)6602020-04-292026-11-12
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
Durvalumab, Bevacizumab, Placebo - Hepatocellular Carcinoma
Phase 3CompletedAstraZeneca9082019-04-292026-10-08
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Cetuximab, Durvalumab, Intensity-Modulated Radiation Therapy - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma
Phase 2 / Phase 3CompletedNational Cancer Institute (NCI)1962018-04-032026-08-27
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Docetaxel, Durvalumab, Laboratory Biomarker Analysis - Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Phase 2 / Phase 3CompletedSWOG Cancer Research Network1162014-07-312023-05-25
Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
Carboplatin, Cisplatin, Durvalumab - Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
Phase 3Active not recruitingRadiation Therapy Oncology Group3302014-01-032026-06-08

Conditions studied

Carcinoma, Non-Small-Cell Lung (6)  ·  Lung Neoplasms (4)  ·  Biliary Tract Neoplasms (2)  ·  Carcinoma, Hepatocellular (2)  ·  Carcinoma (1)  ·  Cholangiocarcinoma (1)  ·  Endometrial Neoplasms (1)  ·  Gallbladder Neoplasms (1)  ·  Hypopharyngeal Neoplasms (1)  ·  Laryngeal Neoplasms (1)  ·  Liver Neoplasms (1)  ·  Mesothelioma (1)  ·  Mesothelioma, Malignant (1)  ·  Mouth Neoplasms (1)  ·  Oropharyngeal Neoplasms (1)

Sponsors

National Cancer Institute (NCI) (6)  ·  AstraZeneca (4)  ·  NRG Oncology (2)  ·  Association NVALT Studies (1)  ·  ECOG-ACRIN Cancer Research Group (1)  ·  Leiden University Medical Center (1)  ·  PrECOG, LLC. (1)  ·  Radiation Therapy Oncology Group (1)  ·  SWOG Cancer Research Network (1)  ·  Stanford University (1)

Countries

United States (15)  ·  Canada (7)  ·  France (4)  ·  Germany (4)  ·  Italy (4)  ·  Netherlands (4)  ·  Australia (3)  ·  Brazil (3)  ·  China (3)  ·  Japan (3)  ·  Poland (3)  ·  South Korea (3)  ·  Taiwan (3)  ·  Thailand (3)  ·  Turkey (Türkiye) (3)

Top investigators

Anna Nowak, MD (1)  ·  Charles B Simone (1)  ·  Deirdre J Cohen (1)  ·  Dirk De Ruysscher, MD PhD (1)  ·  Dwight H Owen (1)  ·  Erin F Cobain (1)  ·  Jean H Hoffman-Censits (1)  ·  Jennifer Knox, MD (1)  ·  Jennifer Y Wo (1)  ·  Jeremy P Cetnar (1)  ·  Jia Fan, PhD (1)  ·  Judith R Kroep, MD PhD (1)  ·  Lizza Hendriks, MD PhD (1)  ·  Loren K Mell (1)  ·  Maximilian Diehn, MD (1)

Results publications

PMID 32615102, PMID 33358660, PMID 34499875, PMID 36600534, PMID 39551064, PMID 39615497, PMID 40966692, PMID 42335416

NIH funding

U10CA180820 (4), U10CA180868 (4), U10CA180888 (3), 2018 (1), 2023 (1), U10CA021661 (1)